{"id":9472,"date":"2013-01-01T05:41:49","date_gmt":"2013-01-01T05:41:49","guid":{"rendered":"http:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/can-fite-reports-promising-results-for-psoriasis-drug\/"},"modified":"2013-01-01T05:41:49","modified_gmt":"2013-01-01T05:41:49","slug":"can-fite-reports-promising-results-for-psoriasis-drug","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/transhuman-news-blog\/psoriasis\/can-fite-reports-promising-results-for-psoriasis-drug\/","title":{"rendered":"Can-Fite reports promising results for psoriasis drug"},"content":{"rendered":"<p><p>        Can-Fite drug could bring fresh        hope to psoriasis sufferers. Photo by Reuters      <\/p>\n<p>          related articles        <\/p>\n<p>            By Asaf Rothem            | Dec.31,2012            | 12:00 PM          <\/p>\n<p>            By Sarit            Menachem | Dec.31,2012 | 12:00 PM          <\/p>\n<p>            By Vadim            Sviderski | Dec.31,2012 | 12:00 PM          <\/p>\n<p>      Can-Fite Biopharma on Sunday reported positive intermediate      results for its Phase II clinical trials of the drug CF-101      to treat moderate to severe psoriasis.    <\/p>\n<p>      Based on the results from the first 103 patients, Can-Fite is      recruiting more patients for a 300-person trial that will      span the United States, Europe and Israel.    <\/p>\n<p>      Psoriasis is an autoimmune skin disease that affects between      two percent and three percent of people. The market for      psoriasis drugs is estimated at $3.6 billion per year, 67      percent of which belongs to biopharmaceuticals (as opposed to      \"chemical\" drugs).    <\/p>\n<p>      Administered monotherapy, the efficacy of CF 101 increased in      a linear fashion throughout the 24-week trial, according to      analysis of the results by a third-party firm. In that CF 101      was similar to competing drugs in advanced development,      including Cellgene's Apremilast. Another is Pfizer's      Tofacitinib, which was recently approved by the U.S. Food and      Drug Administration.    <\/p>\n<p>      Completing the Phase II trial will cost $1 million, projects      Can-Fite CEO Pnina Fishman.    <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>See the original post:<br \/>\n<a target=\"_blank\" href=\"http:\/\/www.haaretz.com\/business\/can-fite-reports-promising-results-for-psoriasis-drug-1.491041\" title=\"Can-Fite reports promising results for psoriasis drug\">Can-Fite reports promising results for psoriasis drug<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Can-Fite drug could bring fresh hope to psoriasis sufferers. Photo by Reuters related articles By Asaf Rothem | Dec.31,2012 | 12:00 PM By Sarit Menachem | Dec.31,2012 | 12:00 PM By Vadim Sviderski | Dec.31,2012 | 12:00 PM Can-Fite Biopharma on Sunday reported positive intermediate results for its Phase II clinical trials of the drug CF-101 to treat moderate to severe psoriasis.  <a href=\"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/transhuman-news-blog\/psoriasis\/can-fite-reports-promising-results-for-psoriasis-drug\/\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-9472","post","type-post","status-publish","format-standard","hentry","category-psoriasis"],"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/9472"}],"collection":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/comments?post=9472"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/9472\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/media?parent=9472"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/categories?post=9472"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/tags?post=9472"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}